⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PCVX News
Vaxcyte, Inc. Common Stock
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
PCVX
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
globenewswire.com
PCVX
VERA
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
globenewswire.com
PCVX
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
globenewswire.com
PCVX
Form 8-K
sec.gov
PCVX
Form 8-K
sec.gov
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
PCVX
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
globenewswire.com
PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
globenewswire.com
PCVX
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
globenewswire.com
PCVX